Aim: This prospective study aimed to envisage the putative prognostic significance of clinical and hematologic parameters in advanced non-small-cell lung cancer patients treated with nivolumab. Materials & methods: Correlations of several parameters with disease control and survival outcomes were provided. Results: A total of 54 patients were included. An ECOG performance status 0-1, the lack of liver and bone metastases and a timeframe from the last systemic treatment ≥4 months correlated with better disease control. The same was observed for baseline low levels of white blood cells and neutrophils, for high levels of NK cells and a neutrophil/lymphocyte ratio <4. The mentioned parameters were also associated with longer overall survival. Conclusion: Nivolumab efficacy in non-small-cell lung cancer patients is influenced by clinicopathological parameters and specific leucocyte subsets.
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab / Facchinetti, Francesco*; Veneziani, Michele; Buti, Sebastiano; Gelsomino, Francesco; Squadrilli, Anna; Bordi, Paola; Bersanelli, Melissa; Cosenza, Agnese; Ferri, Leonarda; Rapacchi, Elena; Mazzaschi, Giulia; Leonardi, Francesco; Quaini, Federico; Ardizzoni, Andrea; Missale, Gabriele; Tiseo, Marcello. - In: IMMUNOTHERAPY. - ISSN 1750-743X. - STAMPA. - 10:8(2018), pp. 681-694. [10.2217/imt-2017-0175]
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab
Gelsomino, Francesco;Ardizzoni, Andrea;
2018
Abstract
Aim: This prospective study aimed to envisage the putative prognostic significance of clinical and hematologic parameters in advanced non-small-cell lung cancer patients treated with nivolumab. Materials & methods: Correlations of several parameters with disease control and survival outcomes were provided. Results: A total of 54 patients were included. An ECOG performance status 0-1, the lack of liver and bone metastases and a timeframe from the last systemic treatment ≥4 months correlated with better disease control. The same was observed for baseline low levels of white blood cells and neutrophils, for high levels of NK cells and a neutrophil/lymphocyte ratio <4. The mentioned parameters were also associated with longer overall survival. Conclusion: Nivolumab efficacy in non-small-cell lung cancer patients is influenced by clinicopathological parameters and specific leucocyte subsets.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
